Fosfomycin tromethamine

Drug Profile

Fosfomycin tromethamine

Alternative Names: Fosfomycin trometamol; FZ 588; Monofoscin; Monuril; Monurol; Urizone; Z 1282

Latest Information Update: 09 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zambon Group SpA
  • Developer Adcock Ingram Pharmaceuticals; Allergan; Inpharzam Ricerche S.A.; Mayne Pharma Group; Orion; Rontag; Roux Ocefa; Zambon Company SpA
  • Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Urinary tract infections

Most Recent Events

  • 25 Sep 2017 Launched for Urinary tract infections in Turkey, Mexico, Indonesia, Taiwan, Philippines, Malaysia, Lebanon, Hong Kong, China, Thailand, Israel, Peru, Tunisia, Slovenia, Russia (PO)
  • 15 Sep 2017 Fosfomycin tromethamine licensed to Mayne Pharma Group in Australia
  • 04 Sep 2017 Registered for Urinary tract infections (In adolescents, In adults) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top